News
CELU
2.460
+9.33%
0.210
Weekly Report: what happened at CELU last week (1104-1108)?
Weekly Report · 6d ago
Based on the provided financial report articles, the title of the article is: "Form 10-Q for Celularity Inc. for the quarterly period ended June 30, 2024
Press release · 11/07 21:18
BUZZ-U.S. STOCKS ON THE MOVE-BorgWarner, Digital Realty, Take-Two
Reuters · 11/07 19:04
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 11/07 16:31
BUZZ-U.S. STOCKS ON THE MOVE-Ralph Lauren, CoreCivic, WK Kellogg
Reuters · 11/07 15:52
Celularity Raises FY24 Expected Net Sales Guidance From $50M-$56M To $54M-$60M
Benzinga · 11/07 13:22
Celularity raises FY24 revenue view to $54M-$60M from $50M-$56M
TipRanks · 11/07 13:10
*Celularity Sees 2024 Sales $54M-$60M >CELU
Dow Jones · 11/07 13:02
CELULARITY INC: RAISES FULL YEAR 2024 EXPECTED NET SALES GUIDANCE TO $54 MLN TO $60 MLN
Reuters · 11/07 13:00
Press Release: Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
Dow Jones · 11/07 13:00
Weekly Report: what happened at CELU last week (1028-1101)?
Weekly Report · 11/04 09:49
Weekly Report: what happened at CELU last week (1021-1025)?
Weekly Report · 10/28 09:45
Based on the provided financial report articles, the title of the article is: "Form 10-Q for Celularity Inc. for the quarterly period ended March 31, 2024
Press release · 10/26 06:16
Celularity files amended compliance plan with Nasdaq Hearings Panel
TipRanks · 10/23 12:35
CELULARITY INC: FILES APPEAL REQUEST AND AMENDED COMPLIANCE PLAN WITH NASDAQ HEARINGS PANEL
Reuters · 10/23 12:32
Celularity to submit 510(k) notification for Tendon Wrap in early 2025
TipRanks · 10/22 12:41
Celularity Provides Corporate Update; Says The Acquisition Of Rebound Adds To Our Portfolio Of Placental-Derived Advanced Biomaterial Products, Sales Of Which Through The First Half Of 2024 Were In Excess Of $24M; Guidance Of Expected Combined Net Sales Of Our Advanced Biomaterial Product And Biobanking Businesses To Be In The Range Of $50M-$56M
Benzinga · 10/22 12:33
CELULARITY : INTEND TO FILE FORM 10-Q FOR Q2 2024 WITHIN COMING WEEKS
Reuters · 10/22 12:30
CELULARITY PROVIDES CORPORATE UPDATE
Reuters · 10/22 12:30
Celularity Inc: Current report
Press release · 10/21 12:06
More
Webull provides a variety of real-time CELU stock news. You can receive the latest news about Celularity Inc through multiple platforms. This information may help you make smarter investment decisions.
About CELU
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).